The new, marquee peer-reviewed journal publishing outstanding original research and perspectives across all facets of the biotech industry


New Expert Panel Discussion

Digitizing Biology: The Roswell Molecular Electronics Platform for Biosensing

Read Now

Sign up for Briefings in Biotechnology, the free monthly eNewsletter delivering critical research updates and industry news spanning the entire scope of biotechnology

Get Started

Meet the Editor-in-Chief

Hana El-Samad, PhD

Hana El-Samad, PhD

Kuo Family Endowed Professor and Vice Chair
Department of Biochemistry and Biophysics
University of California, San Francisco (UCSF)

Hana El-Samad, PhD is currently the Kuo Family Endowed Professor and Vice Chair in the Department of Biochemistry and Biophysics at the University of California, San Francisco (UCSF). Her lab designs programmable, plug-and-play cellular circuits that can be broadly deployed for therapeutic and biotechnological applications, including cell-based immunotherapies, metabolic engineering and bioremediation. Dr. El-Samad is the recipient of numerous prestigious awards including the Donald P. Eckman Award in 2011 and the CSB2 prize in Systems Biology in 2012. She is a former Packard Fellow, a Paul. G. Allen Distinguished Investigator and was named a senior investigator of the Chan-Zuckerberg Biohub in 2017. In 2020, Dr. El-Samad was elected as an American Institute for Medical and Biological Engineering (AIMBE) fellow.


Q&A with Hana El-Samad, Editor-in-Chief


About GEN Biotechnology

The biotech industry is booming, with records being set across the board – the annual number of new drugs winning approval; the number of companies going public; the number of professionals working in biotech; the amount of funding; and the new technologies fueling further progress and innovation in the industry. New technologies such as CRISPR have sparked an entire sub-industry around genome editing, leading to cures for devastating diseases less than a decade post development. From next-gen sequencing and organs-on-chips to synthetic biology and spatial biology, the list goes on.

GEN Biotechnology is the new peer-reviewed journal from Mary Ann Liebert, Inc. and Genetic Engineering & Biotechnology News (GEN) delivering exceptional research breakthroughs, news, and analysis directly impacting biotech. Published bimonthly in print and online with flexible open access options, the Journal provides a dynamic forum aimed at unifying both traditional academic audiences and executives and researchers from across the industry.

An Introduction to GEN Biotechnology

With Kevin Davies, PhD, Executive Editor

Why should your library subscribe to GEN Biotechnology now?

Watch a 3-minute video with Kevin Davies, PhD, Executive Editor, and Wendy Newsham, Director of Global Sales.

Manuscript Submissions

The GEN Biotechnology editorial team is committed to providing rapid, constructive peer review, and prompt decisions for authors. Authors submitting manuscripts early will have the best chance of being included in the coveted inaugural issue in 2022. GEN Biotechnology will publish original research articles and reports, reviews, opinion/guest commentaries, and riveting news and insights across all aspects of biotechnology, including:

  • Drug discovery
  • Cell and gene therapy
  • Immunotherapy
  • Genome editing
  • Genomics
  • AI/Data
  • Bio-engineering
  • Neuroscience
  • Cancer research
  • Diagnostics
  • Translational research
  • Multiomics
  • Agbiotech
  • Environmental biotechnology
  • Precision Medicine
  • Single-cell Biology


Editorial Inquiries

Kevin Davies

Dr. Kevin Davies Executive Editor


Subscriptions and Site-Wide Access

Wendy Newsham

Wendy Newsham Director of Global Sales


Advertising and Sponsorship

Jane Woolf

Jayne Woolf Director, Special Sales